RxDoctor Payments Data

Alexander Wang, MD

Neurology · Cleveland, OHNPI 1972967487

Payments from drug & device makers

$46,340in general payments, 2019–2025

Across 162 payments — averaging $286.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$22K
  • Abbott$15K
  • Boston Scientific$6K
  • Teva Pharmaceuticals USA, Inc.$654
  • UCB, Inc.$289
  • Acadia Pharmaceuticals Inc$205
  • plus $2K from 34 others

What the payments were for

  • Grants$40,00086%
  • Travel & lodging$1,7944%
  • Food & beverage$4,2689%
  • Education$2771%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$46,340 in reported general payments places this provider in the 75th percentile of 702 neurology providers in Ohio.

See all neurology providers in Ohio

Medicare billing

Part B allowed, 2024
$80,090
Medicare patients
224
Services billed
5,119

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate41$381,150
Austedo XrDeutetrabenazine27$203,889
Tetrabenazine12$105,666
RytaryCarbidopa/Levodopa16$55,245
Nurtec OdtRimegepant Sulfate25$30,277
NeuproRotigotine11$17,234
Aimovig AutoinjectorErenumab-Aooe16$14,653
Carbidopa-LevodopaCarbidopa/Levodopa124$4,163
Rivastigmine13$3,204
Primidone83$1,720
Pregabalin44$1,391
Gabapentin63$1,257
Carbidopa-Levodopa ErCarbidopa/Levodopa28$1,182
RivastigmineRivastigmine Tartrate19$1,063
AmantadineAmantadine Hcl17$756

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$181$381,15041 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$654$203,88927 claims
Amneal Pharmaceuticals LLCRytary$195$55,24516 claims
PfizerNurtec Odt$28$30,27725 claims
UCB, Inc.Neupro$289$17,23411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 702 neurology providers in Ohio.

Other neurology in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →